Director of $IMRX purchases 3,000 shares in insider buy.

A recent purchase of company shares by a director at $IMRX has caught the attention of investors and insiders. Diana Hausman, a director at $IMRX, recently acquired 3,000 shares of the company in a significant transaction. This move was made apparent through data obtained from a recent SEC filing, shedding light on insider activity within the company.

Previous transactions of $IMRX stock conducted by insiders have shown an inclination towards purchasing rather than selling. Over the past six months, insiders have engaged in 12 open-market transactions involving $IMRX stock, all of which consisted of purchases. The most recent purchases include those made by key figures within the company, such as Thomas J. Schall, Benjamin J. Zeskind, Peter Feinberg, Brett Matthew Hall, Diana Hausman, Harold Eugene Brakewood, and Leah R. Neufeld.

Looking at hedge fund activity surrounding $IMRX, there have been notable movements in institutional investors’ portfolios. Some institutions have added to their holdings while others have decreased their positions in the company. One notable addition was made by Marshall Wace, LLP, which added a substantial 786,537 shares to their portfolio in the first quarter of 2025. On the other hand, institutions like Rockefeller Capital Management L.P., Price T Rowe Associates Inc /MD/, Millennium Management LLC, TD Asset Management Inc, Corient Private Wealth LLC, and Exchange Traded Concepts, LLC made reductions to their $IMRX stock holdings during the same period.

Analyst ratings on $IMRX have also been released in recent months. One firm, Oppenheimer, issued an “Outperform” rating for the stock on 05/07/2025, reflecting positive sentiments towards the company’s performance. This rating provides investors with valuable insights into the analysts’ perspective on the stock’s future outlook and potential growth opportunities.

Investors and market participants can track these insider transactions, hedge fund activity, and analyst ratings through Quiver Quantitative’s specialized dashboards. These tools offer a comprehensive overview of the company’s performance, market sentiment, and potential opportunities for investors. However, it is essential to note that this article does not constitute financial advice, and readers are encouraged to review Quiver Quantitative’s disclaimers for further information on investment decisions.